Protein expression in E. coli

Expert guidance to define the best strain and process for production of your recombinant protein in E. coli

Our expertise covers over 400 successful Escherichia coli expression projects for a wide diversity of recombinant proteins, multiple process developments and efficient transfers to GMP manufacturing.

Escherichia coli, the expression platform of choice

Escherichia coli is the expression platform in 40% of all of GTP's recombinant protein projects. E.coli genetics are better understood than those of any other microorganism. Thanks to its high yields combined with low production costs, Escherichia coli is the most widely used host for recombinant protein expression.

Whether your project aims to develop a therapeutic or a vaccine, to produce a reagent for research studies or to develop a diagnostic tool, we always consider E. coli to be an excellent first choice.
We make an exception for the expression of complex proteins that require post-translational modifications, in which case expression systems such as mammalian cellinsect cells or yeasts are preferred.

E. coli

Custom E. coli strain & process development services

To guide you towards the successful production of your recombinant protein in E. coli, we offer custom services that include:

  • E. coli strain development.
  • Generation of research cell bank.
  • Yield optimisation in small-scale feasibility studies for soluble / insoluble, periplasmic/cytoplasmic expressions.
  • Screening and optimisation of critical parameters for solubilisation and refolding.
  • Development of efficient, robust and scalable strategies for batch, fed-batch and chemostat fermentations.

IP issues are crucial for projects that aim for industrial protein production. GTP offers optimized IP-free vectors to improve protein expression and stability.

For very challenging recombinant proteins, classic E. coli expression systems may prove unsuccessful. The GTP team keeps your project on track by evaluating innovative E. coli strains obtained through partnerships with research platforms and technology companies.